| Impact of the M184V resistance mutation on virological efficacy and durability of lamivudine-based dual antiretroviral regimens as maintenance therapy in individuals with … R Gagliardini, A Ciccullo, A Borghetti, F Maggiolo, D Bartolozzi, V Borghi, ... Open forum infectious diseases 5 (6), ofy113, 2018 | 80 | 2018 |
| Two distinct hepatitis C virus genotype 1a clades have different geographical distribution and association with natural resistance to NS3 protease inhibitors A De Luca, S Di Giambenedetto, A Lo Presti, S Sierra, M Prosperi, E Cella, ... Open forum infectious diseases 2 (2), ofv043, 2015 | 55 | 2015 |
| Efficacy and tolerability of lamivudine plus dolutegravir as a switch strategy in a multicentre cohort of patients with suppressed HIV‐1 replication A Borghetti, G Baldin, F Lombardi, A Ciccullo, A Capetti, S Rusconi, ... HIV medicine 19 (7), 452-454, 2018 | 53 | 2018 |
| Efficacy and safety of treatment simplification to atazanavir/ritonavir+ lamivudine in HIV-infected patients with virological suppression: 144 week follow-up of the AtLaS pilot … A Mondi, M Fabbiani, N Ciccarelli, M Colafigli, A D'Avino, A Borghetti, ... Journal of Antimicrobial Chemotherapy 70 (6), 1843-1849, 2015 | 53 | 2015 |
| Atazanavir/ritonavir with lamivudine as maintenance therapy in virologically suppressed HIV-infected patients: 96 week outcomes of a randomized trial M Fabbiani, R Gagliardini, N Ciccarelli, E Quiros Roldan, A Latini, ... Journal of Antimicrobial Chemotherapy 73 (7), 1955-1964, 2018 | 41 | 2018 |
| Efficacy and tolerability of lamivudine plus dolutegravir compared with lamivudine plus boosted PIs in HIV-1 positive individuals with virologic suppression: a retrospective … A Borghetti, F Lombardi, R Gagliardini, G Baldin, A Ciccullo, D Moschese, ... BMC infectious diseases 19, 1-9, 2019 | 33 | 2019 |
| Evolution of blood-associated HIV-1 DNA levels after 48 weeks of switching to atazanavir/ritonavir+ lamivudine dual therapy versus continuing triple therapy in the randomized … F Lombardi, S Belmonti, E Quiros-Roldan, A Latini, A Castagna, ... Journal of Antimicrobial Chemotherapy 72 (7), 2055-2059, 2017 | 33 | 2017 |
| Neuropsychological screening tools in Italian HIV+ patients: A comparison of Montreal cognitive assessment (MoCA) and mini mental state examination (MMSE) B Milanini, N Ciccarelli, M Fabbiani, E Baldonero, S Limiti, R Gagliardini, ... The Clinical Neuropsychologist 30 (sup1), 1457-1468, 2016 | 30 | 2016 |
| Durability of first-line regimens including integrase strand transfer inhibitors (INSTIs): data from a real-life setting A d’Arminio Monforte, A Cozzi-Lepri, A Di Biagio, G Marchetti, ... Journal of Antimicrobial Chemotherapy 74 (5), 1363-1367, 2019 | 29 | 2019 |
| Virological control and metabolic improvement in HIV-infected, virologically suppressed patients switching to lamivudine/dolutegravir dual therapy A Borghetti, G Baldin, A Ciccullo, R Gagliardini, A D'Avino, A Mondi, ... Journal of Antimicrobial Chemotherapy 71 (8), 2359-2361, 2016 | 28 | 2016 |
| Liver fibrosis progression and clinical outcomes are intertwined: role of CD4+ T-cell count and NRTI exposure from a large cohort of HIV/HCV-coinfected patients with detectable … E Focà, M Fabbiani, M Prosperi, EQ Roldan, F Castelli, F Maggiolo, ... Medicine 95 (29), e4091, 2016 | 26 | 2016 |
| Low-level viraemia, measured as viraemia copy-years, as a prognostic factor for medium–long-term all-cause mortality: a MASTER cohort study E Quiros-Roldan, E Raffetti, F Castelli, E Foca, F Castelnuovo, M Di Pietro, ... Journal of Antimicrobial Chemotherapy 71 (12), 3519-3527, 2016 | 22 | 2016 |
| Switch to maraviroc with darunavir/r, both QD, in patients with suppressed HIV-1 was well tolerated but virologically inferior to standard antiretroviral therapy: 48-week … B Rossetti, R Gagliardini, G Meini, G Sterrantino, V Colangeli, MC Re, ... PLoS One 12 (11), e0187393, 2017 | 16 | 2017 |
| Lipid-lowering effect and changes in estimated cardiovascular risk after switching to a tenofovir-containing regimen for the treatment of HIV-infected patients R Gagliardini, M Fabbiani, M Colafigli, A D’Avino, A Mondi, A Borghetti, ... Journal of Chemotherapy 29 (5), 299-307, 2017 | 12 | 2017 |
| An outbreak of acute hepatitis A among young adult men: clinical features and HIV coinfection rate from a large teaching hospital in Rome, Italy A Ciccullo, R Gagliardini, G Baldin, A Borghetti, D Moschese, A Emiliozzi, ... HIV medicine 19 (6), 369-375, 2018 | 11 | 2018 |
| 3-Year efficacy and durability of simplification to single tablet regimens: a comparison between co-formulated efavirenz/emtricitabine/tenofovir and rilpivirine/emtricitabine … R Gagliardini, A Bandera, M Zaccarelli, G Sterrantino, A Latini, A D'Avino, ... Antiviral therapy 23 (2), 139-148, 2018 | 10 | 2018 |
| Pharmacokinetics of etravirine in HIV-infected patients concomitantly treated with rifampin for tuberculosis R Gagliardini, M Fabbiani, S Fortuna, E Visconti, P Navarra, R Cauda, ... Infection 42, 775-778, 2014 | 9 | 2014 |
| Liver fibrosis is associated with cognitive impairment in people living with HIV N Ciccarelli, M Fabbiani, AC Brita, R De Marco, P Grima, R Gagliardini, ... Infection 47, 589-593, 2019 | 4 | 2019 |
| Italian expert panel consensus statements on two-drug antiretroviral regimens to treat naïve and virologically suppressed HIV-1 infected patients A Antinori, MM Santoro, R Gagliardini, G Marchetti, A Mondi, V Cento, ... New Microbiol 42 (2), 69-80, 2019 | 4 | 2019 |
| HIV-1 non-R5 tropism correlates with a larger size of the cellular viral reservoir and a detectable residual viremia in patients under suppressive ART F Lombardi, S Belmonti, L Rapone, A Borghetti, A Ciccullo, R Gagliardini, ... Journal of Clinical Virology 103, 57-62, 2018 | 4 | 2018 |
